Belatacept: Where the BENEFITS Outweigh the Risk

Am J Kidney Dis. 2017 May;69(5):561-563. doi: 10.1053/j.ajkd.2017.02.007.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Abatacept*
  • Cyclosporine*
  • Graft Rejection
  • Graft Survival
  • Humans
  • Immunoconjugates
  • Immunosuppressive Agents
  • Kidney Transplantation

Substances

  • Immunoconjugates
  • Immunosuppressive Agents
  • Abatacept
  • Cyclosporine